Race Is On For Psychedelic DMT-Related Compounds, Small Pharma, Inc To Issue Two New Patents

Race Is On For Psychedelic DMT-Related Compounds, Small Pharma, Inc To Issue Two New Patents

After the positive results provided by its clinical trial assessing novel DMT’s effects on patients with Major Depressive Disorder (MDD), psychedelics biotech Small Pharma Inc. DMTTF is updating its IP portfolio following the United States Patent and Trademark Office (USPTO)’s notice of allowance to filing a patent application covering composition of matter, therapeutic compositions and uses of a group of deuterated DMT compounds.

The USPTO will soon grant the company a patent protecting composition of matter for certain deuterated homologs of certain tryptamine compounds, including the active ingredients being tested in the SPL-029 oral tryptamine series, as well as therapeutic compositions of the deuterated tryptamines, including orally active formulations.

See also: Cybin Approved For First In-Human Dosing Of DMT Molecule CYB004, Milestone For Anxiety Disorder Treatment

Small Pharma’s multi-layered patent strategy targets key areas of protection across its research and development pipeline. 

For SPL026, this includes an optimized injectable formulation for extended shelf life and a synthetic, Good Manufacturing Process (GMP)-compliant route. For pipeline candidate SPL028 and the SPL029 series that means protection on the composition of matter of the deuterated compounds as well as on their medical use and therapeutic composition.

“Innovating on known compounds has always been the foundation of Small Pharma’s vision, and we continue to explore ways to innovate on our assets to optimize their clinical and commercial potential,” said CEO George Tziras, who reaffirms the company’s commitment to bringing “novel scalable and reimbursable short-duration treatments to mental health patients.” 

Tziras added that building a robust IP position is central to protecting these innovations and allowing pipeline programs to work toward developing a proprietary position in key markets such as the U.S. and Europe.

Photo: Benzinga edit with photo by CDC on Pexels and Jynto on Wikimedia Commons.

Posted In: CannabisNewsPenny StocksPsychedelicsGuidanceLegalManagementGlobalMarketsDMT EntitiesPsychedelic-Assisted TherapiesShort-Acting PsychedelicsUnited States Patent and Trademark Office (USPTO)


Meet the biggest cannabis industry players and make deals that will push the industry forward.

Featuring live company presentations, insider panels, and unmatched access to networking, the Benzinga Cannabis Capital Conference is where cannabis executives and entrepreneurs meet.

Join us April 11-12, 2023 at Fontainebleau Miami Beach in sunny Florida.